Source: www.novartis.com
The US Food and Drug Administration (FDA) has granted Novartis Breakthrough Therapy designation for its investigational therapy crizanlizumab (SEG101). This revolutionary treatment is designed to help prevent vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD). VOCs occur when multiple blood cells stick to each other and to blood vessels, causing blockages. VOCs are unpredictable and extremely painful events that can lead to serious acute and chronic complications.
